Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 2.14
FOLD's Cash-to-Debt is ranked lower than
72% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. FOLD: 2.14 )
Ranked among companies with meaningful Cash-to-Debt only.
FOLD' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.14  Med: 45.98 Max: No Debt
Current: 2.14
Equity-to-Asset 0.35
FOLD's Equity-to-Asset is ranked lower than
79% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. FOLD: 0.35 )
Ranked among companies with meaningful Equity-to-Asset only.
FOLD' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.58 Max: 0.84
Current: 0.35
0.35
0.84
Piotroski F-Score: 4
Altman Z-Score: -0.50
Beneish M-Score: 12.83
WACC vs ROIC
14.86%
-107.29%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -3668.62
FOLD's Operating Margin % is ranked lower than
86% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. FOLD: -3668.62 )
Ranked among companies with meaningful Operating Margin % only.
FOLD' s Operating Margin % Range Over the Past 10 Years
Min: -17680.72  Med: -2567.54 Max: -11.42
Current: -3668.62
-17680.72
-11.42
Net Margin % -4034.73
FOLD's Net Margin % is ranked lower than
88% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. FOLD: -4034.73 )
Ranked among companies with meaningful Net Margin % only.
FOLD' s Net Margin % Range Over the Past 10 Years
Min: -16427.82  Med: -2307.57 Max: -10.2
Current: -4034.73
-16427.82
-10.2
ROE % -59.17
FOLD's ROE % is ranked lower than
62% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. FOLD: -59.17 )
Ranked among companies with meaningful ROE % only.
FOLD' s ROE % Range Over the Past 10 Years
Min: -322.07  Med: -81.22 Max: -9.19
Current: -59.17
-322.07
-9.19
ROA % -21.55
FOLD's ROA % is ranked higher than
59% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. FOLD: -21.55 )
Ranked among companies with meaningful ROA % only.
FOLD' s ROA % Range Over the Past 10 Years
Min: -55.51  Med: -38.58 Max: -6.13
Current: -21.55
-55.51
-6.13
ROC (Joel Greenblatt) % -2215.68
FOLD's ROC (Joel Greenblatt) % is ranked lower than
70% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. FOLD: -2215.68 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
FOLD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2904.44  Med: -1492.62 Max: -134.99
Current: -2215.68
-2904.44
-134.99
3-Year Revenue Growth Rate 74.20
FOLD's 3-Year Revenue Growth Rate is ranked higher than
92% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. FOLD: 74.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
FOLD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -59.1 Max: 74.2
Current: 74.2
0
74.2
3-Year EBITDA Growth Rate 6.60
FOLD's 3-Year EBITDA Growth Rate is ranked higher than
57% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. FOLD: 6.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
FOLD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -85.6  Med: -12.95 Max: 81.7
Current: 6.6
-85.6
81.7
3-Year EPS without NRI Growth Rate 8.70
FOLD's 3-Year EPS without NRI Growth Rate is ranked higher than
61% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. FOLD: 8.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
FOLD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -85.2  Med: -12.15 Max: 54.5
Current: 8.7
-85.2
54.5
GuruFocus has detected 3 Warning Signs with Amicus Therapeutics Inc $FOLD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» FOLD's 10-Y Financials

Financials (Next Earnings Date: 2017-05-24 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

FOLD Guru Trades in Q1 2016

Paul Tudor Jones 16,950 sh (New)
RS Investment Management 3,527,703 sh (+1.11%)
Louis Moore Bacon Sold Out
Chuck Royce Sold Out
» More
Q2 2016

FOLD Guru Trades in Q2 2016

Paul Tudor Jones 72,981 sh (+330.57%)
RS Investment Management 3,429,187 sh (-2.79%)
» More
Q3 2016

FOLD Guru Trades in Q3 2016

Jim Simons 196,400 sh (New)
Paul Tudor Jones Sold Out
» More
Q4 2016

FOLD Guru Trades in Q4 2016

Paul Tudor Jones 51,290 sh (New)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with FOLD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:XLRN, NAS:FPRX, OTCPK:PFSCF, OTCPK:BPMUF, NAS:EPZM, OTCPK:GNFTF, NAS:ALDR, NAS:INSM, NAS:CHRS, NAS:XNCR, NAS:CORT, NAS:AIMT, NAS:ASND, NAS:RGEN, NYSE:EBS, NAS:ACOR, NAS:ESPR, NAS:LOXO, NAS:AMRN, NAS:JNCE » details
Traded in other countries:AM6.Germany,
Amicus Therapeutics Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of next-generation medicines for orphan diseases.

Amicus Therapeutics Inc is a global biotechnology company that aims to treat rare and orphan diseases. The company's strategy focuses on global capacity with an international infrastructure, late-stage product acquisition, and biologics manufacturing. Amicus leverages its pharmacological technology to develop treatments for human genetic diseases by targeting mutated proteins. The company utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products.

Ratios

vs
industry
vs
history
PB Ratio 2.97
FOLD's PB Ratio is ranked higher than
60% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. FOLD: 2.97 )
Ranked among companies with meaningful PB Ratio only.
FOLD' s PB Ratio Range Over the Past 10 Years
Min: 0.87  Med: 3.15 Max: 14.52
Current: 2.97
0.87
14.52
PS Ratio 208.33
FOLD's PS Ratio is ranked lower than
91% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. FOLD: 208.33 )
Ranked among companies with meaningful PS Ratio only.
FOLD' s PS Ratio Range Over the Past 10 Years
Min: 0.84  Med: 31.57 Max: 4540
Current: 208.33
0.84
4540
Current Ratio 3.06
FOLD's Current Ratio is ranked lower than
61% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. FOLD: 3.06 )
Ranked among companies with meaningful Current Ratio only.
FOLD' s Current Ratio Range Over the Past 10 Years
Min: 2.94  Med: 7.43 Max: 11.32
Current: 3.06
2.94
11.32
Quick Ratio 3.03
FOLD's Quick Ratio is ranked lower than
57% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. FOLD: 3.03 )
Ranked among companies with meaningful Quick Ratio only.
FOLD' s Quick Ratio Range Over the Past 10 Years
Min: 2.94  Med: 7.43 Max: 11.32
Current: 3.03
2.94
11.32
Days Inventory 601.26
FOLD's Days Inventory is ranked lower than
97% of the 384 Companies
in the Global Biotechnology industry.

( Industry Median: 132.21 vs. FOLD: 601.26 )
Ranked among companies with meaningful Days Inventory only.
FOLD' s Days Inventory Range Over the Past 10 Years
Min: 601.26  Med: 748.4 Max: 748.4
Current: 601.26
601.26
748.4
Days Sales Outstanding 96.00
FOLD's Days Sales Outstanding is ranked lower than
71% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. FOLD: 96.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
FOLD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.94  Med: 90.94 Max: 1088.97
Current: 96
63.94
1088.97
Days Payable 5.00
FOLD's Days Payable is ranked lower than
91% of the 353 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. FOLD: 5.00 )
Ranked among companies with meaningful Days Payable only.
FOLD' s Days Payable Range Over the Past 10 Years
Min: 5  Med: 5654.65 Max: 5654.65
Current: 5
5
5654.65

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -30.40
FOLD's 3-Year Average Share Buyback Ratio is ranked lower than
80% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. FOLD: -30.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
FOLD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -317.5  Med: -33.25 Max: -15.3
Current: -30.4
-317.5
-15.3

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 6.58
FOLD's Price-to-Median-PS-Value is ranked lower than
94% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. FOLD: 6.58 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
FOLD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.04  Med: 2.37 Max: 14.6
Current: 6.58
0.04
14.6
Earnings Yield (Greenblatt) % -22.19
FOLD's Earnings Yield (Greenblatt) % is ranked lower than
77% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. FOLD: -22.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
FOLD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -23.19  Med: 98.9 Max: 913.7
Current: -22.19
-23.19
913.7

More Statistics

Revenue (TTM) (Mil) $4.96
EPS (TTM) $ -1.50
Beta1.74
Short Percentage of Float48.84%
52-Week Range $4.41 - 9.83
Shares Outstanding (Mil)142.74
» More Articles for FOLD

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Globus Medical Inc, Diplomat Pharmacy Inc, Zendesk Inc, and Amicus Thera Mar 28 2015 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Nov 09 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Aug 06 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) May 07 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Nov 04 2009 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Aug 06 2009 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) May 08 2009 

More From Other Websites
Today's Research Reports on Biotech Stocks to Watch: Amicus Therapeutics and Sarepta Therapeutics Mar 17 2017
Amicus Therapeutics Launches Galafold™ (Migalastat) for Treatment of Fabry Disease in Italy Mar 08 2017
AMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 08 2017
Harry Boxer’s six biotechnology stocks to watch Mar 07 2017
AMICUS THERAPEUTICS INC Financials Mar 07 2017
Four biotech stocks surging on optimism about drug trials, product launches Mar 03 2017
Biotechs Breaking Out On Drug Development News Mar 02 2017
Amicus Therapeutics, Inc. (FOLD) Could Be The Force That Brings Change To The FDA Mar 02 2017
Dow Soars Above 21,000 for the First Time in History: Today's Reports on Clean Energy Fuels and... Mar 02 2017
Amicus Therapeutics to Present at Upcoming Investor Conferences Mar 02 2017
Edited Transcript of FOLD earnings conference call or presentation 1-Mar-17 1:30pm GMT Mar 01 2017
Amicus Therapeutics CEO: Trump constructive for our indus... Mar 01 2017
4 Biopharma Stocks Moving the Market on Wednesday Mar 01 2017
AMICUS THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 01 2017
Amicus CEO John Crowley, Not His Daughter Megan, Might Compel Trump to Make Big Changes at FDA Mar 01 2017
Q4 2016 Amicus Therapeutics Inc Earnings Release - Before Market Open Mar 01 2017
Amicus Therapeutics Announces Full-Year 2016 Financial Results and Corporate Updates Mar 01 2017
Amicus Therapeutics Launches Galafold in UK Feb 28 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)